Integra Lifesciences Holdings Stock Total Debt

IART Stock

USD 24.54 0.84 3.54%

Integra LifeSciences Holdings fundamentals help investors to digest information that contributes to Integra LifeSciences' financial success or failures. It also enables traders to predict the movement of Integra Stock. The fundamental analysis module provides a way to measure Integra LifeSciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Integra LifeSciences stock.

Other Current Liab Total Assets

Total Debt To Capitalization is likely to drop to 0.34 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Integra LifeSciences Holdings Company Total Debt Analysis

Integra LifeSciences' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Total Debt

Bonds

+

Notes

More About Total Debt | All Equity Analysis

Current Integra LifeSciences Total Debt

1.68 B

Most of Integra LifeSciences' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Integra LifeSciences Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Integra Total Debt Driver Correlations

Understanding the fundamental principles of building solid financial models for Integra LifeSciences is extremely important. It helps to project a fair market value of Integra Stock properly, considering its historical fundamentals such as Total Debt. Since Integra LifeSciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Integra LifeSciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Integra LifeSciences' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Short Term Investments	Short Term Debt	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Good Will	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Long Term Investments	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.97	0.94	0.83	0.86	0.96	0.99	0.96	0.97	0.68	0.02	0.86	0.86	-0.04	0.94	0.57	0.99	-0.67	0.89	0.87	0.17	-0.03	0.84	0.69	0.77	0.54
Total Stockholder Equity	0.97		0.84	0.87	0.82	0.92	0.92	0.96	0.92	0.7	0.05	0.85	0.77	-0.11	0.94	0.45	0.95	-0.52	0.79	0.91	0.16	-0.01	0.87	0.73	0.82	0.55
Net Debt	0.94	0.84		0.69	0.88	0.95	0.98	0.84	0.96	0.57	-0.03	0.8	0.9	0.08	0.88	0.68	0.96	-0.84	0.94	0.74	0.19	-0.07	0.72	0.49	0.56	0.48
Retained Earnings	0.83	0.87	0.69		0.71	0.74	0.78	0.86	0.71	0.88	-0.1	0.56	0.54	-0.37	0.82	0.41	0.79	-0.21	0.59	0.72	0.02	-0.15	0.7	0.88	0.85	0.76
Accounts Payable	0.86	0.82	0.88	0.71		0.93	0.86	0.78	0.85	0.48	-0.15	0.73	0.75	-0.02	0.88	0.56	0.87	-0.63	0.78	0.7	0.04	-0.19	0.72	0.44	0.49	0.48
Net Receivables	0.96	0.92	0.95	0.74	0.93		0.96	0.89	0.96	0.53	0.01	0.86	0.86	-0.01	0.96	0.59	0.97	-0.72	0.87	0.81	0.17	-0.03	0.8	0.5	0.59	0.46
Total Liab	0.99	0.92	0.98	0.78	0.86	0.96		0.93	0.98	0.65	0.01	0.85	0.9	0.02	0.92	0.64	0.99	-0.76	0.94	0.82	0.18	-0.04	0.8	0.63	0.71	0.52
Total Current Assets	0.96	0.96	0.84	0.86	0.78	0.89	0.93		0.88	0.69	0.0	0.81	0.81	-0.18	0.9	0.51	0.92	-0.51	0.83	0.84	0.03	-0.05	0.82	0.76	0.86	0.53
Intangible Assets	0.97	0.92	0.96	0.71	0.85	0.96	0.98	0.88		0.58	0.05	0.88	0.9	0.11	0.9	0.61	0.99	-0.81	0.93	0.84	0.27	0.0	0.81	0.56	0.66	0.45
Short Term Investments	0.68	0.7	0.57	0.88	0.48	0.53	0.65	0.69	0.58		-0.11	0.38	0.38	-0.2	0.62	0.26	0.66	-0.14	0.48	0.65	0.04	-0.16	0.6	0.87	0.82	0.82
Short Term Debt	0.02	0.05	-0.03	-0.1	-0.15	0.01	0.01	0.0	0.05	-0.11		0.31	0.03	0.32	0.05	0.24	0.03	-0.06	0.0	-0.01	0.5	1.0	-0.09	-0.04	-0.02	-0.1
Common Stock	0.86	0.85	0.8	0.56	0.73	0.86	0.85	0.81	0.88	0.38	0.31		0.9	0.21	0.8	0.59	0.87	-0.7	0.87	0.84	0.25	0.27	0.84	0.39	0.59	0.13
Long Term Debt	0.86	0.77	0.9	0.54	0.75	0.86	0.9	0.81	0.9	0.38	0.03	0.9		0.09	0.76	0.74	0.87	-0.84	0.98	0.76	0.17	-0.01	0.75	0.38	0.54	0.11
Treasury Stock	-0.04	-0.11	0.08	-0.37	-0.02	-0.01	0.02	-0.18	0.11	-0.2	0.32	0.21	0.09		-0.15	-0.13	0.04	-0.39	0.16	-0.04	-0.04	0.33	0.12	-0.29	-0.19	-0.2
Property Plant Equipment	0.94	0.94	0.88	0.82	0.88	0.96	0.92	0.9	0.9	0.62	0.05	0.8	0.76	-0.15		0.56	0.93	-0.56	0.77	0.83	0.25	0.01	0.76	0.57	0.63	0.56
Current Deferred Revenue	0.57	0.45	0.68	0.41	0.56	0.59	0.64	0.51	0.61	0.26	0.24	0.59	0.74	-0.13	0.56		0.58	-0.66	0.71	0.38	0.46	0.22	0.24	0.25	0.24	0.12
Good Will	0.99	0.95	0.96	0.79	0.87	0.97	0.99	0.92	0.99	0.66	0.03	0.87	0.87	0.04	0.93	0.58		-0.73	0.9	0.86	0.2	-0.02	0.84	0.63	0.72	0.54
Net Tangible Assets	-0.67	-0.52	-0.84	-0.21	-0.63	-0.72	-0.76	-0.51	-0.81	-0.14	-0.06	-0.7	-0.84	-0.39	-0.56	-0.66	-0.73		-0.86	-0.48	-0.31	-0.04	-0.47	-0.1	-0.2	-0.08
Long Term Debt Total	0.89	0.79	0.94	0.59	0.78	0.87	0.94	0.83	0.93	0.48	0.0	0.87	0.98	0.16	0.77	0.71	0.9	-0.86		0.76	0.13	-0.04	0.77	0.46	0.6	0.24
Capital Surpluse	0.87	0.91	0.74	0.72	0.7	0.81	0.82	0.84	0.84	0.65	-0.01	0.84	0.76	-0.04	0.83	0.38	0.86	-0.48	0.76		0.23	-0.06	0.93	0.58	0.76	0.33
Deferred Long Term Liab	0.17	0.16	0.19	0.02	0.04	0.17	0.18	0.03	0.27	0.04	0.5	0.25	0.17	-0.04	0.25	0.46	0.2	-0.31	0.13	0.23		0.5	-0.08	-0.02	-0.08	0.02
Short Long Term Debt	-0.03	-0.01	-0.07	-0.15	-0.19	-0.03	-0.04	-0.05	0.0	-0.16	1.0	0.27	-0.01	0.33	0.01	0.22	-0.02	-0.04	-0.04	-0.06	0.5		-0.14	-0.1	-0.08	-0.13
Long Term Investments	0.84	0.87	0.72	0.7	0.72	0.8	0.8	0.82	0.81	0.6	-0.09	0.84	0.75	0.12	0.76	0.24	0.84	-0.47	0.77	0.93	-0.08	-0.14		0.55	0.76	0.3
Net Invested Capital	0.69	0.73	0.49	0.88	0.44	0.5	0.63	0.76	0.56	0.87	-0.04	0.39	0.38	-0.29	0.57	0.25	0.63	-0.1	0.46	0.58	-0.02	-0.1	0.55		0.93	0.75
Net Working Capital	0.77	0.82	0.56	0.85	0.49	0.59	0.71	0.86	0.66	0.82	-0.02	0.59	0.54	-0.19	0.63	0.24	0.72	-0.2	0.6	0.76	-0.08	-0.08	0.76	0.93		0.57
Capital Stock	0.54	0.55	0.48	0.76	0.48	0.46	0.52	0.53	0.45	0.82	-0.1	0.13	0.11	-0.2	0.56	0.12	0.54	-0.08	0.24	0.33	0.02	-0.13	0.3	0.75	0.57

Click cells to compare fundamentals

Integra Total Debt Historical Pattern

Today, most investors in Integra LifeSciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Integra LifeSciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Integra LifeSciences total debt as a starting point in their analysis.

Integra LifeSciences Total Debt

Timeline

In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Competition

Predict Integra LifeSciences

Short Long Term Debt Total Over Time

Integra Net Debt

Net Debt

1.48 Billion

At this time, Integra LifeSciences' Net Debt is comparatively stable compared to the past year.

Based on the latest financial disclosure, Integra LifeSciences Holdings has a Total Debt of 1.68 B. This is 38.87% lower than that of the Health Care Equipment & Supplies sector and 3.74% lower than that of the Health Care industry. The total debt for all United States stocks is 68.37% higher than that of the company.

Integra Total Debt Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Integra LifeSciences' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Integra LifeSciences could also be used in its relative valuation, which is a method of valuing Integra LifeSciences by comparing valuation metrics of similar companies.

Integra LifeSciences is currently under evaluation in total debt category among its peers.

Integra LifeSciences ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Integra LifeSciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Integra LifeSciences' managers, analysts, and investors.

Environmental

Governance

Social

Integra LifeSciences Institutional Holders

Institutional Holdings refers to the ownership stake in Integra LifeSciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Integra LifeSciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Integra LifeSciences' value.

		Shares
Capital Research Global Investors	2024-09-30	1.3 M
Voloridge Investment Management, Llc	2024-09-30	1.1 M
D. E. Shaw & Co Lp	2024-09-30	1 M
Charles Schwab Investment Management Inc	2024-09-30	944.3 K
Neuberger Berman Group Llc	2024-06-30	828.5 K
Northern Trust Corp	2024-09-30	812.3 K
Glenmede Trust Co Na	2024-09-30	727.8 K
Lord, Abbett & Co Llc	2024-09-30	713.3 K
Norges Bank	2024-06-30	686.8 K
Blackrock Inc	2024-06-30	11.3 M
Morgan Stanley - Brokerage Accounts	2024-06-30	11 M

Integra Fundamentals

	Return On Equity	-0.0042
	Return On Asset	0.0302
	Profit Margin	(0) %
	Operating Margin	0.07 %
	Current Valuation	3.61 B
	Shares Outstanding	77.16 M
	Shares Owned By Insiders	3.21 %
	Shares Owned By Institutions	93.25 %
	Number Of Shares Shorted	4.1 M
	Price To Earning	26.94 X
	Price To Book	1.20 X
	Price To Sales	1.21 X
	Revenue	1.54 B
	Gross Profit	982.03 M
	EBITDA	274.01 M
	Net Income	67.74 M
	Cash And Equivalents	451.52 M
	Cash Per Share	5.41 X
	Total Debt	1.68 B
	Debt To Equity	1.03 %
	Current Ratio	3.85 X
	Book Value Per Share	19.73 X
	Cash Flow From Operations	139.96 M
	Short Ratio	4.10 X
	Earnings Per Share	(0.09) X
	Price To Earnings To Growth	0.79 X
	Target Price	28.11
	Number Of Employees	3.95 K
	Beta	1.08
	Market Capitalization	1.89 B
	Total Asset	3.78 B
	Retained Earnings	946.86 M
	Working Capital	751.06 M
	Current Asset	438.5 M
	Current Liabilities	139.13 M
	Net Asset	3.78 B

About Integra LifeSciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Integra LifeSciences Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Integra LifeSciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Integra LifeSciences Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Integra Stock Analysis

When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC